Orbimed Advisors LLC Athenex, Inc. Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$4.08 - $14.75 $15.1 Million - $54.5 Million	-3,694,061 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$11.06 - $14.01 $3.14 Million - $3.98 Million	-283,889 Reduced 7.14%	3,694,061 $40.9 Million
Q3 2020 Nov 16, 2020	SELL	$10.26 - $14.55 $322,122 - $456,811	-31,396 Reduced 0.78%	3,977,950 $48.1 Million
Q1 2020 May 15, 2020	BUY	$5.71 - $15.85 $7.06 Million - $19.6 Million	1,237,125 Added 44.63%	4,009,346 $31 Million
Q4 2019 Feb 14, 2020	SELL	$9.6 - $17.75 $5.15 Million - $9.53 Million	-536,699 Reduced 16.22%	2,772,221 $42.3 Million
Q3 2019 Nov 14, 2019	SELL	$12.16 - $21.0 $6.46 Million - $11.2 Million	-531,210 Reduced 13.83%	3,308,920 $40.3 Million
Q2 2019 Aug 14, 2019	BUY	$9.44 - $19.8 $32.2 Million - $67.5 Million	3,410,130 Added 793.05%	3,840,130 $76 Million
Q1 2018 May 15, 2018	BUY	$13.53 - $17.47 $5.82 Million - $7.51 Million	430,000 New	430,000 $7.31 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.